This morning Seeking Alpha ran an article suggesting that Neuralstem Inc.'s (CUR) stock price might be flat for an extended period. This is interesting and unlikely for at least three reasons:
First, CUR has closed at prices varying from $0.45 to $1.42 since August 24. Two stock offerings have closed since mid August, one priced at $.040 and the follow up at $1.00.
Second, during the same period CUR has announced good results from both clinical and pre-clinical trials. The roller coaster ride in stock price has resulted from positive trial results versus the two dilutive events.
Third, in the two clinical trials CUR has underway, one for amyotrophic lateral sclerosis (ALS) and the other for major depresive disorder (MDD) -- this trial is particularly unique -- CUR will report results by the end of 2012 or in the first calendar quarter of 2013.
Comments